E-LIB Suche - Ergebnisse für: Janssens, Ann

1

First-line venetoclax combinations versus chemoimmunotherap..:

Fürstenau, Moritz ; Kater, Arnon P ; Robrecht, Sandra...
The Lancet Oncology. 25 (2024) 6 - p. 744-759 , 2024

Link: https://doi.org/10.1016/..

2

Phase 3 SELENE Study: Ibrutinib Plus BR/R-CHOP in Previousl..:

Nastoupil, Loretta J ; Hess, Georg ; Pavlovsky, Miguel Arturo...
Blood Advances. , 2023

Link: https://doi.org/10.1182/..

3

Fixed-duration ibrutinib–venetoclax versus chlorambucil–obi..:

Niemann, Carsten U ; Munir, Talha ; Moreno, Carol...
The Lancet Oncology. 24 (2023) 12 - p. 1423-1433 , 2023

Link: https://doi.org/10.1016/..

4

S148: TIME-LIMITED VENETOCLAX AND IBRUTINIB FOR PATIENTS WI..:

Kater, Arnon ; Dubois, Julie ; Brieghel, Christian...
HemaSphere. 7 (2023) S3 - p. e10648ed , 2023

Link: https://doi.org/10.1097/..

5

Catastrophic antiphospholipid syndrome in an immune thrombo..:

Van de Vondel, Saartje ; Vandenbriele, Christophe ; Gheysens, Gerald..
Research and Practice in Thrombosis and Haemostasis. 7 (2023) 3 - p. 100125 , 2023

Link: https://doi.org/10.1016/..

6

CLL-106 First Prospective Data on Minimal Residual Disease ..:

Munir, Talha ; Moreno, Carol ; Owen, Carolyn...
Clinical Lymphoma Myeloma and Leukemia. 22 (2022) - p. S264-S265 , 2022

Link: https://doi.org/10.1016/..

7

Immunochemotherapy and Maintenance With Obinutuzumab or Rit..:

Herold, Michael ; Hoster, Eva ; Janssens, Ann...
HemaSphere. 6 (2022) 3 - p. e699 , 2022

Link: https://doi.org/10.1097/..

8

Poster: CLL-106 First Prospective Data on Minimal Residual ..:

Munir, Talha ; Moreno, Carol ; Owen, Carolyn...
Clinical Lymphoma Myeloma and Leukemia. 22 (2022) - p. S138 , 2022

Link: https://doi.org/10.1016/..

9

Effectiveness and Safety of Ibrutinib for Chronic Lymphocyt..:

Janssens, Ann ; Berneman, Zwi N. ; Offner, Fritz...
Clinical Hematology International. 4 (2022) 4 - p. 133-143 , 2022

Link: https://doi.org/10.1007/..

10

Efficacy and safety in a 4-year follow-up of the ELEVATE-TN..:

Sharman, Jeff P. ; Egyed, Miklos ; Jurczak, Wojciech...
Leukemia. 36 (2022) 4 - p. 1171-1175 , 2022

Link: https://doi.org/10.1038/..

11

Oral Abstract: CLL-106 First Prospective Data on Minimal Re..:

Munir, Talha ; Moreno, Carol ; Owen, Carolyn...
Clinical Lymphoma Myeloma and Leukemia. 22 (2022) - p. S116 , 2022

Link: https://doi.org/10.1016/..

12

A phase 3, randomized study of ofatumumab combined with ben..:

Rummel, Mathias J. ; Janssens, Ann ; MacDonald, David...
British Journal of Haematology. 193 (2021) 6 - p. 1123-1133 , 2021

Link: https://doi.org/10.1111/..

13

Poster: CLL-139: Acalabrutinib ± Obinutuzumab vs Obinutuzum..:

Sharman, Jeff P. ; Egyed, Miklos ; Jurczak, Wojciech...
Clinical Lymphoma Myeloma and Leukemia. 21 (2021) - p. S220 , 2021

Link: https://doi.org/10.1016/..

14

BIRD-2, a BH4-domain-targeting peptide of Bcl-2, provokes B..:

Kerkhofs, Martijn ; La Rovere, Rita ; Welkenhuysen, Kirsten...
Cell Calcium. 94 (2021) - p. 102333 , 2021

Link: https://doi.org/10.1016/..

15

CLL-139: Acalabrutinib ± Obinutuzumab vs Obinutuzumab + Chl..:

Sharman, Jeff P. ; Egyed, Miklos ; Jurczak, Wojciech...
Clinical Lymphoma Myeloma and Leukemia. 21 (2021) - p. S318-S319 , 2021

Link: https://doi.org/10.1016/..